IMPRIMIS PHARMACEUTICALS, INC. (IMMY) Files An 8-K Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition.

On November 14, 2016, Imprimis Pharmaceuticals, Inc. (the
Company) issued a press release announcing its financial results
for the third quarter ended September 30, 2016. The press release
is being furnished as Exhibit 99.1 to this Current Report on Form
8-K.

Item 7.01 Regulation FD Disclosure

Attached as Exhibit 99.2 to this Item 7.01 is a presentation that
is being used by the management of the Company at investor
conferences and at meetings describing the Company.

The information furnished under this Items 2.02 and 7.01 of this
Current Report on Form 8-K, including Exhibits 99.1 and 99.2,
shall not be deemed to be filed for the purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the Exchange
Act), or otherwise subject to the liabilities of that Section.
The information in this Item 2.02 and 7.01, including Exhibit
99.1 and 99.2, shall not be deemed incorporated by reference into
any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except to the extent it is specifically
incorporated by reference but regardless of any general
incorporation language in such filing.

The information furnished under this Items 2.02 and 7.01 of this
Current Report on Form 8-K, including Exhibits 99.1 and 99.2,
shall not be deemed to constitute an admission that such
information or exhibit is required to be furnished to Regulation
FD or that such information or exhibit contains material
information that is not otherwise publicly available. In
addition, the Company does not assume any obligation to update
such information or exhibit in the future.

Item 9.01. Financial Statements and Exhibits

About IMPRIMIS PHARMACEUTICALS, INC. (IMMY)